Vera Therapeutics Aims for Mid-2026 Launch of Atacicept After FDA Priority Review
Event summary
- Vera Therapeutics reported a net loss of $299.6 million for 2025, up from $152.1 million in 2024.
- FDA granted priority review to atacicept's BLA with a PDUFA date of July 7, 2026.
- Company raised $800 million in equity and debt financings in 2025.
- Positive Phase 3 data from ORIGIN 3 study presented at ASN Kidney Week and published in NEJM.
- Potential commercial launch of atacicept expected in mid-2026.
The big picture
Vera Therapeutics is positioning itself as a leader in the IgA nephropathy space with the potential approval of atacicept. The company's strong financial position, bolstered by recent financings, suggests it can weather the costs of commercialization. The biotech sector is closely watching how Vera's regulatory strategy and commercial execution will play out, as success could set a precedent for other autoimmune kidney disease treatments.
What we're watching
- Regulatory Approval
- Whether the FDA will approve atacicept by the July 7, 2026 PDUFA date and the potential impact on Vera's market position.
- Commercial Execution
- The pace at which Vera can successfully launch atacicept in the U.S. market if approved.
- Financial Sustainability
- How long Vera's current cash reserves will last post-launch and whether additional funding will be required.
Related topics